消癌平注射液联合化疗治疗中晚期食管癌的疗效和安全性
目的探讨消癌平注射液联合化疗治疗中晚期食管癌的疗效和安全性。方法选取临床确诊的中晚期食管癌、KPS评分≥60分，预计生存时间≥3个月的患者124例，采取多中心、随机、开放、平行对照试验设计，将患者分为试验组和对照组，每组62例，试验组接受消癌平注射液联合替吉奥＋顺铂化疗方案，对照组单用替吉奥＋顺铂化疗方案，21 d为1个治疗周期，观察两组患者的疗效和不良反应。结果试验组和对照组可评价临床疗效的患者分别为57例和55例。试验组和对照组患者的有效率分别为54.4%和34.5%，疾病控制率分别为86.0%和69.1%，试验组患者的有效率和疾病控制率均明显高于对照组，差异有统计学意义（均P〈0.05）...
Saved in:
| Published in | 中华肿瘤杂志 Vol. 39; no. 6; pp. 453 - 457 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | Chinese |
| Published |
450052,郑州大学第一附属医院肿瘤科%455000,安阳市肿瘤医院肿瘤 内科%吉林大学中日联谊医院放射治疗科, 长春,130033%471009,洛阳市中心医院肿瘤科%河南大学淮河医院肿瘤科, 开封,475000
2017
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0253-3766 |
| DOI | 10.3760/cma.j.issn.0253-3766.2017.06.010 |
Cover
| Abstract | 目的探讨消癌平注射液联合化疗治疗中晚期食管癌的疗效和安全性。方法选取临床确诊的中晚期食管癌、KPS评分≥60分，预计生存时间≥3个月的患者124例，采取多中心、随机、开放、平行对照试验设计，将患者分为试验组和对照组，每组62例，试验组接受消癌平注射液联合替吉奥＋顺铂化疗方案，对照组单用替吉奥＋顺铂化疗方案，21 d为1个治疗周期，观察两组患者的疗效和不良反应。结果试验组和对照组可评价临床疗效的患者分别为57例和55例。试验组和对照组患者的有效率分别为54.4%和34.5%，疾病控制率分别为86.0%和69.1%，试验组患者的有效率和疾病控制率均明显高于对照组，差异有统计学意义（均P〈0.05）。试验组和对照组患者的中位无进展生存时间分别为7.97和6.43个月，差异有统计学意义（P＝0.033）；试验组和对照组患者的中位总生存时间分别为12.93和10.93个月，差异有统计学意义（P＝0.023）。两组患者常见的不良反应为恶心呕吐、血小板减少、血红蛋白减少、中性粒细胞减少、白细胞减少、肝功能损害、色素沉着、口腔黏膜炎、肾功能损害和腹泻等，其中试验组患者恶心呕吐、血小板减少、白细胞减少、中性粒细胞减少和腹泻的发生率明显低于对照组，差异有统计学意义（均P〈0.05）。结论消癌平注射液联合替吉奥＋顺铂化疗方案治疗中晚期食管癌患者，可明显提高近期疗效，延长患者的生存时间，降低化疗不良反应，给患者带来临床收益。 |
|---|---|
| AbstractList | 目的探讨消癌平注射液联合化疗治疗中晚期食管癌的疗效和安全性。方法选取临床确诊的中晚期食管癌、KPS评分≥60分，预计生存时间≥3个月的患者124例，采取多中心、随机、开放、平行对照试验设计，将患者分为试验组和对照组，每组62例，试验组接受消癌平注射液联合替吉奥＋顺铂化疗方案，对照组单用替吉奥＋顺铂化疗方案，21 d为1个治疗周期，观察两组患者的疗效和不良反应。结果试验组和对照组可评价临床疗效的患者分别为57例和55例。试验组和对照组患者的有效率分别为54.4%和34.5%，疾病控制率分别为86.0%和69.1%，试验组患者的有效率和疾病控制率均明显高于对照组，差异有统计学意义（均P〈0.05）。试验组和对照组患者的中位无进展生存时间分别为7.97和6.43个月，差异有统计学意义（P＝0.033）；试验组和对照组患者的中位总生存时间分别为12.93和10.93个月，差异有统计学意义（P＝0.023）。两组患者常见的不良反应为恶心呕吐、血小板减少、血红蛋白减少、中性粒细胞减少、白细胞减少、肝功能损害、色素沉着、口腔黏膜炎、肾功能损害和腹泻等，其中试验组患者恶心呕吐、血小板减少、白细胞减少、中性粒细胞减少和腹泻的发生率明显低于对照组，差异有统计学意义（均P〈0.05）。结论消癌平注射液联合替吉奥＋顺铂化疗方案治疗中晚期食管癌患者，可明显提高近期疗效，延长患者的生存时间，降低化疗不良反应，给患者带来临床收益。 目的 探讨消癌平注射液联合化疗治疗中晚期食管癌的疗效和安全性. 方法 选取临床确诊的中晚期食管癌、KPS评分≥60分,预计生存时间≥3个月的患者124例,采取多中心、随机、开放、平行对照试验设计,将患者分为试验组和对照组,每组62例,试验组接受消癌平注射液联合替吉奥+顺铂化疗方案,对照组单用替吉奥+顺铂化疗方案,21 d为1个治疗周期,观察两组患者的疗效和不良反应. 结果 试验组和对照组可评价临床疗效的患者分别为57例和55例.试验组和对照组患者的有效率分别为54.4%和34.5%,疾病控制率分别为86.0%和69.1%,试验组患者的有效率和疾病控制率均明显高于对照组,差异有统计学意义(均P<0.05).试验组和对照组患者的中位无进展生存时间分别为7.97和6.43个月,差异有统计学意义(P=0.033);试验组和对照组患者的中位总生存时间分别为12.93和10.93个月,差异有统计学意义(P=0.023).两组患者常见的不良反应为恶心呕吐、血小板减少、血红蛋白减少、中性粒细胞减少、白细胞减少、肝功能损害、色素沉着、口腔黏膜炎、肾功能损害和腹泻等,其中试验组患者恶心呕吐、血小板减少、白细胞减少、中性粒细胞减少和腹泻的发生率明显低于对照组,差异有统计学意义(均P<0.05). 结论 消癌平注射液联合替吉奥+顺铂化疗方案治疗中晚期食管癌患者,可明显提高近期疗效,延长患者的生存时间,降低化疗不良反应,给患者带来临床收益. |
| Abstract_FL | Objective To evaluate the efficacy and safety of Xiaoaiping combined with chemotherapy in the treatment of advanced esophageal cancer.Methods This is a multi-center, randomized, open label and parallel controlled study.A total of 124 advanced esophageal cancer patients with Karnofsky Performance Status (KPS) score ≥60 and expected survival time≥3 months were enrolled.We adopted design and divided the patients into study and control group.The patients in study group received Xiaoaiping combined with S-1 and cisplatin.The control group received S-1 and cisplatin.Each group included 62 patients and 21 days as a treatment cycle.The efficacy and adverse events in patients of the two groups were observed and compared.Results 57 patients in the study group and 55 in the control group were included in efficacy assessment.The response rate was 54.4% and 34.5% in the study group and control group, respectively(P<0.05).Disease control rates were 86.0% and 69.1%, respectively(P<0.05).The median progression-free survival (PFS) was 7.97 in the study group and 6.43 months in the control group(P<0.05).The median overall survival(OS) was 12.93 in the study group and 10.93 months in the control group(P<0.05).The most common adverse events in the two groups were nausea and vomiting, thrombocytopenia, anemia, neutropenia, liver damage, pigmentation, oral mucositis, renal impairment and diarrhea.The incidences of nausea, vomiting, thrombocytopenia, leukopenia, neutropenia and diarrhea in the study group were significantly higher than those in the control group(P<0.05).Conclusion Xiaoaiping combined with S-1 and cisplatin significantly increased response rate, and prolongedpatients′ survival in patients with advanced esophageal cancer. |
| Author | 王峰 樊青霞 王洪海 韩东梅 宋娜莎 卢红 |
| AuthorAffiliation | 郑州大学第一附属医院肿瘤科,450052 安阳市肿瘤医院肿瘤内科,455000 吉林大学中日联谊医院放射治疗科,长春130033 洛阳市中心医院肿瘤科,471009 河南大学淮河医院肿瘤科,开封475000 |
| AuthorAffiliation_xml | – name: 450052,郑州大学第一附属医院肿瘤科%455000,安阳市肿瘤医院肿瘤 内科%吉林大学中日联谊医院放射治疗科, 长春,130033%471009,洛阳市中心医院肿瘤科%河南大学淮河医院肿瘤科, 开封,475000 |
| Author_FL | Han Dongmei Lu Hong Fan Qingxia Song Nasha Wang Feng Wang Honghai |
| Author_FL_xml | – sequence: 1 fullname: Wang Feng – sequence: 2 fullname: Fan Qingxia – sequence: 3 fullname: Wang Honghai – sequence: 4 fullname: Han Dongmei – sequence: 5 fullname: Song Nasha – sequence: 6 fullname: Lu Hong |
| Author_xml | – sequence: 1 fullname: 王峰 樊青霞 王洪海 韩东梅 宋娜莎 卢红 |
| BookMark | eNo9j01LAlEUhu_CIDP_RBC0mel-zNy5swzpi4Q27uXOdUZHdCyHiFwVGCi4iChDCSRa5CYJBSn6O9079S-6YsSBc-A9D-d9zxpIRY3IB2ALQZM4FG6LOjerZhjHkQmxTQwtUhND5JiQmhDBFEj_66sgG8ehB21EKCOIpsGRmneSQU9-zNRsLN_aaj79vrqTNx3Z6yf9BzX91P3r_VUNhupx9PM8SiZPmk-G7cX2viNve3LSlddjdfmyDlYCXov97N_MgMLebiF3YOSP9w9zO3lD2A4yStyzPMY8CweBTkks6jLGbI4wK4kStLnwELY8wXyOhfB1WOFSRiF2A5f5hJMM2FyePedRwKNysdo4a0basNiqtGqLzyGFCGluY8mJSiMqn4aaPGmGdd68KFIHW7qYS34BogV5pg |
| ContentType | Journal Article |
| Copyright | Copyright © Wanfang Data Co. Ltd. All Rights Reserved. |
| Copyright_xml | – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved. |
| DBID | 2RA 92L CQIGP W91 ~WA 2B. 4A8 92I 93N PSX TCJ |
| DOI | 10.3760/cma.j.issn.0253-3766.2017.06.010 |
| DatabaseName | 维普期刊资源整合服务平台 中文科技期刊数据库-CALIS站点 中文科技期刊数据库-7.0平台 中文科技期刊数据库-医药卫生 中文科技期刊数据库- 镜像站点 Wanfang Data Journals - Hong Kong WANFANG Data Centre Wanfang Data Journals 万方数据期刊 - 香港版 China Online Journals (COJ) China Online Journals (COJ) |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| DocumentTitleAlternate | Efficacy and safety of Xiaoaiping combined with chemotherapy in the treatment of advanced esophageal cancer |
| DocumentTitle_FL | Efficacy and safety of Xiaoaiping combined with chemotherapy in the treatment of advanced esophageal cancer |
| EndPage | 457 |
| ExternalDocumentID | zhzl201706011 672424289 |
| GroupedDBID | --- -05 123 2B. 2C~ 2RA 92F 92I 92L ABDBF ACGFS ALMA_UNASSIGNED_HOLDINGS CCEZO CIEJG CQIGP CW9 EOJEC OBODZ TCJ TGQ U1G U5O W91 ~WA 4A8 93N ABJNI ACUHS PSX |
| ID | FETCH-LOGICAL-c571-dab4b88b42ff01734698885a128dcd05acb124bc8ea2cceb05c9686029f98e3a3 |
| ISSN | 0253-3766 |
| IngestDate | Thu May 29 04:00:01 EDT 2025 Wed Feb 14 10:00:20 EST 2024 |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 6 |
| Keywords | 消癌平注射液 药物疗法 替吉奥 S-1 食管肿瘤 Esophageal neoplasms Xiaoaiping injection Drug therapy |
| Language | Chinese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c571-dab4b88b42ff01734698885a128dcd05acb124bc8ea2cceb05c9686029f98e3a3 |
| Notes | Wang Feng, Fan Qingxia, Wang Honghai, Han Dongmei, Song Nasha, Lu Hong （Depratement of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China ; Depratement of Medical Oncology, Anyang Tumor hospital, Anyang, 455000, China ; Department of Radiotherapy, China-Japan Union Hospital of Jilin University, Changchun, 130033, China; Department of Oncology, Luoyang Central Hospital, Luoyang, 471009, China; Department of Oncology, Huaihe Hospitalof Henan University, Kaifeng, 475000, China） 11-2152/R ObjectiveTo evaluate the efficacy and safety of Xiaoaiping combined with chemotherapy in the treatment of advanced esophageal cancer.MethodsThis is a multi-center, randomized, open label and parallel controlled study. A total of 124 advanced esophageal cancer patients with Karnofsky Performance Status （KPS） score ≥60 and expected survival time≥3 months were enrolled. We adopted design and divided the patients into study and control group. The patients in study group received Xiaoaiping combin |
| PageCount | 5 |
| ParticipantIDs | wanfang_journals_zhzl201706011 chongqing_primary_672424289 |
| PublicationCentury | 2000 |
| PublicationDate | 2017 |
| PublicationDateYYYYMMDD | 2017-01-01 |
| PublicationDate_xml | – year: 2017 text: 2017 |
| PublicationDecade | 2010 |
| PublicationTitle | 中华肿瘤杂志 |
| PublicationTitleAlternate | Chinese Journal of Oncology |
| PublicationTitle_FL | Chinese Journal of Oncology |
| PublicationYear | 2017 |
| Publisher | 450052,郑州大学第一附属医院肿瘤科%455000,安阳市肿瘤医院肿瘤 内科%吉林大学中日联谊医院放射治疗科, 长春,130033%471009,洛阳市中心医院肿瘤科%河南大学淮河医院肿瘤科, 开封,475000 |
| Publisher_xml | – name: 450052,郑州大学第一附属医院肿瘤科%455000,安阳市肿瘤医院肿瘤 内科%吉林大学中日联谊医院放射治疗科, 长春,130033%471009,洛阳市中心医院肿瘤科%河南大学淮河医院肿瘤科, 开封,475000 |
| SSID | ssib051368316 ssib007279245 ssib000995398 ssj0042033 ssib017477325 ssib006576341 ssib001103529 ssib058574917 |
| Score | 2.1216853 |
| Snippet | 目的探讨消癌平注射液联合化疗治疗中晚期食管癌的疗效和安全性。方法选取临床确诊的中晚期食管癌、KPS评分≥60分，预计生存时间≥3个月的患者124例，采取多中心、随机、开放、平行对照试验设计，将患者分为试验组和对照组，每组62例，试验组接受消癌平注射液联合替吉奥＋顺铂化疗方案，对照组单用替吉奥＋顺铂化疗方案，21... 目的 探讨消癌平注射液联合化疗治疗中晚期食管癌的疗效和安全性. 方法 选取临床确诊的中晚期食管癌、KPS评分≥60分,预计生存时间≥3个月的患者124例,采取多中心、随机、开放、平行对照试验设计,将患者分为试验组和对照组,每组62例,试验组接受消癌平注射液联合替吉奥+顺铂化疗方案,对照组单用替吉奥+顺铂化疗方案,21... |
| SourceID | wanfang chongqing |
| SourceType | Aggregation Database Publisher |
| StartPage | 453 |
| SubjectTerms | 替吉奥 消癌平注射液 药物疗法 食管肿瘤 |
| Title | 消癌平注射液联合化疗治疗中晚期食管癌的疗效和安全性 |
| URI | http://lib.cqvip.com/qk/93685X/201706/672424289.html https://d.wanfangdata.com.cn/periodical/zhzl201706011 |
| Volume | 39 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NaxQxFA_9APEiiopaLT0YEJapO5PJJDl4yHRnKQqeKvS2TGZmW0S3frSXPSlUqNCDiFZahCIe7MUiLRTFf8eZ1f_Cl0y6jSJ-XULIey_vvWQm-WUmeUHocp6JlBeF8mDcE16o0tzjgZ96SgURrIdgRi3Mboub0eyt8Po8nR8ZvebsWlpZVtNZ_5fnSv6nV6EM-lWfkv2Hnh1WCgWQh_6FFHoY0r_qY5xEOI4w5zhhWAjMZ3BCcSxwTAyJYMlNSRPz0DLHAU444EcsQk0STSNOtayITD0RFswwBziOnZIQxxzLliaBLiFNBqTaOBFYEpNhWCZY-o49THNq7U7NglqlIrA2gxQXxgxqbI70DgzJXOjsGABsLcwT4wgYafQKIBkfRUsXaq_bWAxnWc0CEjw2FAJN0tDMoItLbT9IgTE6Ax4lDYcdGiLE0ngbgyhrGK42lsJaBBK6JnCFNg59MWpkTeOmpqRh7QZGqDyWkHE_udRnS-2YHFCix-TInUDqaEz2RXFng7COg2yBRVhH4v55ztK7kuBBy-6m07eNkumhEr3zkJnwsnbr74-RwSOmz_bAinkUjQeM-XQMjcu4Fbcd_CyoG98RsB4A7iP8GsFqkzh4mOlwkke_mWG1yhg5GvCpT-AF1uuJGuqEQZOYLRyHBh9DV6xHV__kj45lsrjUW7gPCM0cmOt1096Cg-3mTqITdlE2Jes37BQa6S-eRjeqg7XB5nr5ab_a3yk_rFYHe18fvyifrZXrG4ONV9XeZ0i_fHxfbW5Vr7e_vd0e7L4B_sHWqqa-XCufr5e7T8snO9Wjd2fQXDuZm5n17NUjXkaZ7-WpChXnKgy6XTCZ6GtWOacpgLk8y5s0zRTgYpXxIg2yrICWyUSkb3MTXcELkpKzaKy31CvOoSl9gyOFJMgAuCu_qXJGctVVPslhGMz4eTQxbIfOvTrCTGfYs-fRpG2Zjh13Hnb6i_07QR32yvcv_FZ8Ah3XnPUnw4tobPnBSnEJQPSymrSPynfDmZmD |
| linkProvider | EBSCOhost |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E6%B6%88%E7%99%8C%E5%B9%B3%E6%B3%A8%E5%B0%84%E6%B6%B2%E8%81%94%E5%90%88%E5%8C%96%E7%96%97%E6%B2%BB%E7%96%97%E4%B8%AD%E6%99%9A%E6%9C%9F%E9%A3%9F%E7%AE%A1%E7%99%8C%E7%9A%84%E7%96%97%E6%95%88%E5%92%8C%E5%AE%89%E5%85%A8%E6%80%A7&rft.jtitle=%E4%B8%AD%E5%8D%8E%E8%82%BF%E7%98%A4%E6%9D%82%E5%BF%97&rft.au=%E7%8E%8B%E5%B3%B0+%E6%A8%8A%E9%9D%92%E9%9C%9E+%E7%8E%8B%E6%B4%AA%E6%B5%B7+%E9%9F%A9%E4%B8%9C%E6%A2%85+%E5%AE%8B%E5%A8%9C%E8%8E%8E+%E5%8D%A2%E7%BA%A2&rft.date=2017&rft.issn=0253-3766&rft.volume=39&rft.issue=6&rft.spage=453&rft.epage=457&rft_id=info:doi/10.3760%2Fcma.j.issn.0253-3766.2017.06.010&rft.externalDocID=672424289 |
| thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F93685X%2F93685X.jpg http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fzhzl%2Fzhzl.jpg |